Birmingham Capital Management Co. Inc. AL Takes $2.71 Million Position in Pfizer Inc. $PFE

Birmingham Capital Management Co. Inc. AL bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 112,751 shares of the biopharmaceutical company's stock, valued at approximately $2,715,000. Pfizer accounts for 1.0% of Birmingham Capital Management Co. Inc. AL's holdings, making the stock its 29th biggest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the second quarter worth approximately $26,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new position in Pfizer during the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock opened at $28.33 on Thursday. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The firm has a fifty day moving average of $25.44 and a 200-day moving average of $26.29. The firm has a market capitalization of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. UBS Group reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Citigroup lifted their target price on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. Finally, Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source